Artivion Earnings Call Highlights Growth Amid Headwinds

Artivion Inc. ((AORT)) has held its Q1 earnings call. Read on for the main highlights of the call.

Artivion’s latest earnings call painted a mixed but generally upbeat picture, with management emphasizing solid double‑digit revenue growth, expanding margins, and rapid deleveraging even as they acknowledged near‑term bumps. Investors heard a credible long‑term growth story built around flagship products and a differentiated aortic arch portfolio, tempered by softer international demand, AMDS rollout friction, and a modest guidance reset.

Strong Quarterly Revenue Growth

Artivion reported first‑quarter 2026 revenues of $116.3 million, representing a 12% year‑over‑year increase on a constant‑currency basis and underscoring resilient demand across its core portfolio. Management framed the quarter as evidence that the company can still post healthy top‑line gains despite regional volatility and product‑specific hiccups.

Adjusted EBITDA Surge and Margin Gains

Profitability outpaced revenue as adjusted EBITDA climbed about 26% to $22.1 million, up from $17.5 million a year earlier, driving an adjusted EBITDA margin of 19%. That marks roughly 130 basis points of margin expansion and signals good operating discipline, with management highlighting leverage in general and administrative costs and stable gross margins.

Product Lines Drive Outperformance

Within the product mix, On‑X mechanical valves stood out with 17% year‑over‑year constant‑currency growth, while tissue processing bounced back 23% as operations normalized after a 2024 cybersecurity event. Stent grafts delivered 10% growth despite constraints, whereas BioGlue was flat, modestly trailing internal expectations but still within typical distributor stocking variability.

AMDS Usage Trends Support Long‑Term Adoption

The company acknowledged that U.S. AMDS starter‑set sales fell short, but emphasized that implant and reorder patterns from existing AMDS accounts were stronger than anticipated. This usage profile supports management’s thesis that once administrative and economic barriers are cleared, AMDS can ramp meaningfully and become a durable growth driver.

Endospan Deal Broadens Aortic Arch Portfolio

Artivion exercised its option to acquire Endospan after U.S. approval of the NEXUS system, completing what management calls a three‑pronged aortic arch strategy alongside AMDS and C‑Branch LSA. A U.S. commercial launch for NEXUS is targeted for early 2027, with the total domestic addressable market estimated near $150 million, including about $100 million for dissection‑focused use.

Pipeline Advances Target Future Growth

Beyond NEXUS, the pipeline is progressing with the ARTISON IDE trial for a next‑generation frozen elephant trunk device now at 26 of 132 patients enrolled, with full enrollment expected by mid‑2027. C‑Branch LSA is tracking toward a potential FDA approval around 2029, which management pegs as an incremental $80 million annual U.S. opportunity layered on top of existing markets.

Balance Sheet Strengthens as Leverage Falls

The balance sheet continued to improve, with net leverage dropping to 1.8 times at the end of March from 4.0 times a year earlier, aided by debt reduction and EBITDA growth. Artivion closed the quarter with about $55.8 million in cash and $215.4 million of debt, while free cash flow was a seasonally weak but significantly improved negative $6.8 million versus a $20.6 million outflow last year.

Guidance Reset Tempers Growth Expectations

In light of first‑quarter shortfalls and persistent uncertainty around a few pockets of the business, Artivion trimmed its 2026 outlook for adjusted constant‑currency revenue growth to 7%–11%, implying reported sales of $480 million to $496 million. The company now sees full‑year adjusted EBITDA at $100 million to $107 million, pointing to double‑digit growth and about 100 basis points of margin expansion at the midpoint before factoring in the Endospan deal.

AMDS Starter‑Set Timing Weighs on Outlook

A major driver of the guidance reset was slower‑than‑expected U.S. AMDS starter‑set adoption, which involves hospitals purchasing an initial four‑unit bundle for around $100,000. Management cited institutional review board delays and hospitals postponing purchases ahead of anticipated approvals, estimating that roughly half the guidance reduction reflects these timing issues rather than demand erosion.

International Markets Show Regional Weakness

Outside the U.S., results were uneven, with EMEA growing 5% and Asia Pacific 6%, both below their usual trajectory, while Latin America declined 23%. Middle East softness and lumpy ordering from distributors weighed particularly on stent graft performance, and management now assumes softer international trends in the near term within its updated outlook.

Supply Constraints Hit Certain Stent Grafts

Stent graft revenue still rose 10% year over year, but management acknowledged that unanticipated supply chain challenges constrained availability for some product variants. The company expects these issues to be resolved, though timing remains uncertain, and has conservatively baked this variability into its updated full‑year guidance.

Acquisition Costs Pressure Near‑Term Earnings

Funding the Endospan acquisition via a planned $150 million term loan will bring strategic benefits but introduce near‑term earnings drag, with about $8 million of incremental expense expected through 2026 for launch and integration. Incorporating those costs, Artivion projects adjusted EBITDA in the $92 million to $99 million range for 2026, still implying growth but at a lower level than the stand‑alone plan.

Cash Flow Improving but Interest Set to Rise

Free cash flow remained negative in the first quarter but showed clear progress, improving to a $6.8 million outflow from more than triple that a year earlier. Interest expense fell to $5.2 million in the period, yet management guided that quarterly interest will rise toward roughly $8 million beginning in the third quarter once the term loan is fully drawn to fund Endospan.

BioGlue Performance Slightly Behind Plan

BioGlue revenue was essentially flat versus the prior year, modestly below management’s goal of mid‑single‑digit growth for the product. Executives framed the shortfall as largely tied to normal distributor stocking patterns rather than structural demand weakness, and signaled no change to the longer‑term role of BioGlue within the portfolio.

Forward‑Looking Guidance and Strategic Outlook

Looking ahead, Artivion is balancing a more cautious near‑term stance with confidence in its multiyear trajectory, calling for mid‑to‑high single‑digit revenue growth and expanding margins in 2026 despite AMDS and stent graft uncertainties. The guidance assumes limited contribution from NEXUS next year, a mid‑year approval milestone for AMDS, and successful closing of the Endospan deal, setting the stage for larger payoff as the aortic arch platform matures.

Artivion’s earnings call leaves investors weighing a credible long‑term growth story against real short‑term frictions, from delayed AMDS starter‑set purchases to choppy international demand and higher interest costs. For now, the company’s expanding margins, deleveraging trend, and deepening aortic arch portfolio suggest that patience may be rewarded if management executes on its remediation plans and pipeline milestones.